Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) will host a teleconference at 8:00 a.m. EDT (7:00 a.m. CDT) on Monday, June 6, 2011, to review data presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of data presented at the meeting on the oncology portfolio and address inquiries from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the call at: http://investor.bms.com or by dialing 913-312-0677, confirmation code: 2538916. A replay of the call will be available beginning at 11:00 a.m. EDT on June 6 through midnight EDT on June 20. The replay can be accessed at http://investor.bms.com or by dialing 402-280-9013, confirmation code: 2538916.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb Company
Media:
Jennifer Fron Mauer, 609-252-6579
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  Illinois  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Other Health

MEDIA:

Logo
 Logo

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.